Literature DB >> 31070727

Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists.

Andrew V Schally1,2,3,4, Xianyang Zhang5, Renzhi Cai1, Joshua M Hare3,5, Riccarda Granata6, Manuela Bartoli7.   

Abstract

In this article, we briefly review the identification of GHRH, provide an abridged overview of GHRH antagonists, and focus on studies with GHRH agonists. Potent GHRH agonists of JI and MR class were synthesized and evaluated biologically. Besides the induction of the release of pituitary GH, GHRH analogs promote cell proliferation and exert stimulatory effects on various tissues, which express GHRH receptors (GHRH-Rs). A large body of work shows that GHRH agonists, such as MR-409, improve pancreatic β-cell proliferation and metabolic functions and facilitate engraftment of islets after transplantation in rodents. Accordingly, GHRH agonists offer a new therapeutic approach to treating diabetes. Various studies demonstrate that GHRH agonists promote repair of cardiac tissue, producing improvement of ejection fraction and reduction of infarct size in rats, reduction of infarct scar in swine, and attenuation of cardiac hypertrophy in mice, suggesting clinical applications. The presence of GHRH-Rs in ocular tissues and neuroprotective effects of GHRH analogs in experimental diabetic retinopathy indicates their possible therapeutic applications for eye diseases. Other effects of GHRH agonists, include acceleration of wound healing, activation of immune cells, and action on the central nervous system. As GHRH might function as a growth factor, we examined effects of GHRH agonists on tumors. In vitro, GHRH agonists stimulate growth of human cancer cells and upregulate GHRH-Rs. However, in vivo, GHRH agonists inhibit growth of human cancers xenografted into nude mice and downregulate pituitary and tumoral GHRH-Rs. Therapeutic applications of GHRH analogs are discussed. The development of GHRH analogs should lead to their clinical use.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31070727     DOI: 10.1210/en.2019-00111

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

1.  GHRH antagonists support lung endothelial barrier function.

Authors:  Mohammad A Uddin; Mohammad S Akhter; Sitanshu S Singh; Khadeja-Tul Kubra; Andrew V Schally; Seetharama Jois; Nektarios Barabutis
Journal:  Tissue Barriers       Date:  2019-10-03

2.  Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke.

Authors:  Yueyang Liu; Jingyu Yang; Xiaohang Che; Jianhua Huang; Xianyang Zhang; Xiaoxiao Fu; Jialing Cai; Yang Yao; Haotian Zhang; Ruiping Cai; Xiaomin Su; Qian Xu; Fu Ren; Renzhi Cai; Andrew V Schally; Ming-Sheng Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

3.  Unfolded protein response in endothelial injury.

Authors:  Nektarios Barabutis
Journal:  Cell Cycle       Date:  2022-05-26       Impact factor: 5.173

4.  A glimpse at growth hormone-releasing hormone cosmos.

Authors:  Nektarios Barabutis
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-04-25       Impact factor: 2.557

5.  Growth hormone releasing hormone in the unfolded protein response context.

Authors:  Nektarios Barabutis
Journal:  Endocrine       Date:  2020-01-20       Impact factor: 3.633

6.  Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.

Authors:  Farzad Izak Shirian; Mohammad Ghorbani; Mohammad E Khamseh; Mehrnaz Imani; Mahshid Panahi; Alimohammad Alimohammadi; Mitra Nourbakhsh; Vahid Salimi; Masoumeh Tavakoli-Yaraki
Journal:  BMC Endocr Disord       Date:  2021-03-18       Impact factor: 2.763

7.  Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.

Authors:  Angela C Rieger; Luiza L Bagno; Alessandro Salerno; Victoria Florea; Jose Rodriguez; Marcos Rosado; Darren Turner; Raul A Dulce; Lauro M Takeuchi; Rosemeire M Kanashiro-Takeuchi; Peter Buchwald; Amarylis C B A Wanschel; Wayne Balkan; Ivonne H Schulman; Andrew V Schally; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-26       Impact factor: 12.779

8.  Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.

Authors:  Lucia Recinella; Annalisa Chiavaroli; Giustino Orlando; Claudio Ferrante; Serena Veschi; Alessandro Cama; Guya Diletta Marconi; Francesca Diomede; Iacopo Gesmundo; Riccarda Granata; Renzhi Cai; Wei Sha; Andrew V Schally; Luigi Brunetti; Sheila Leone
Journal:  Mol Psychiatry       Date:  2021-07-30       Impact factor: 15.992

9.  Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury.

Authors:  Ling-Ping Cen; Tsz Kin Ng; Jia-Jian Liang; Ciyan Xu; Xi Zhuang; Yu-Fen Liu; Shao-Lang Chen; Yanxuan Xu; Qichen Yang; Xiang-Ling Yuan; Yong Jie Qin; Sun On Chan; Haoyu Chen; Mingzhi Zhang; Andrew V Schally; Chi Pui Pang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

10.  Suppression of reactive oxygen species in endothelial cells by an antagonist of growth hormone-releasing hormone.

Authors:  Mohammad S Akhter; Nektarios Barabutis
Journal:  J Biochem Mol Toxicol       Date:  2021-08-08       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.